Ascendis Pharma A/S (ASND) has a negative trailing P/E of -54.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 61.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -1.83%, forward earnings yield 1.64%. PEG 1.18.
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -7.5 | -0.09 | 2.89 | 110.85 | - |
| 2017 | -9.0 | -0.21 | 5.95 | 728.64 | - |
| 2018 | -17.3 | 1.24 | 8.01 | 212.13 | - |
| 2019 | -26.5 | -0.55 | 9.66 | 431.35 | - |
| 2020 | -16.5 | -0.22 | 8.24 | 993.40 | - |
| 2021 | -16.9 | 1.09 | 7.33 | 833.09 | - |
| 2022 | -11.0 | -0.23 | 24.28 | 124.97 | - |
| 2023 | -13.3 | 0.75 | -44.02 | 24.05 | - |
| 2024 | -20.4 | 0.86 | -72.81 | 21.17 | - |
| 2025 | -50.2 | 1.13 | -67.58 | 15.90 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.58 | $4.61M | $-68.51M | -1487.3% |
| 2017 | $-3.68 | $1.53M | $-123.9M | -8097.8% |
| 2018 | $-3.17 | $10.58M | $-130.1M | -1229.5% |
| 2019 | $-4.69 | $13.38M | $-218.02M | -1630% |
| 2020 | $-8.28 | $6.95M | $-418.96M | -6025.5% |
| 2021 | $-7.00 | $7.78M | $-383.58M | -4931.6% |
| 2022 | $-10.40 | $51.17M | $-583.19M | -1139.6% |
| 2023 | $-8.55 | $266.72M | $-481.45M | -180.5% |
| 2024 | $-6.53 | $363.64M | $-378.08M | -104% |
| 2025 | $-3.62 | $691.71M | $-219.03M | -31.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $4.17 | $2.08 – $6.54 | $1.39B | $1.28B – $1.51B | 11 |
| 2027 | $10.57 | $6.18 – $15.21 | $1.99B | $1.73B – $2.18B | 11 |
| 2028 | $15.72 | $9.84 – $22.03 | $2.53B | $2.24B – $2.79B | 6 |
| 2029 | $20.09 | $17.02 – $22.63 | $3.05B | $2.71B – $3.37B | 4 |
| 2030 | $23.01 | $19.49 – $25.91 | $3.41B | $3.02B – $3.76B | 2 |
